Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Federico Nasroulah, Takayuki Yoshino et al.|The Lancet Oncology|2015Cited by 954
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Takayuki Yoshino et al.|The Lancet|2023Cited by 319
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal CancerThierry André, Sara Lonardi, Elena Élez et al.|New England Journal of Medicine|2024Cited by 208
Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized TrialRocio García‐Carbonero, L. Paz-Ares, José Mayordomo et al.|JNCI Journal of the National Cancer Institute|2001Cited by 179
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)Enrique Grande, Rocio García‐Carbonero, Jaume Capdevila et al.|Annals of Oncology|2015Cited by 157